Richard Pazdur worried that his program allowing simultaneous submission and assessment of drug applications in the US and other countries would be improperly linked to, and potentially damaged by, White House plans to allow drug importation from Canada.
The director of the US Food and Drug Administration's Oncology Center of Excellence also was concerned that ex-US drug pricing...






